Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18625716 | 1,3-BIS(NAPHTHALEN-1-YLOXY)PROPAN-2-ONE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | April 2024 | June 2024 | Allow | 2 | 0 | 0 | No | No |
| 18609790 | PHARMACEUTICAL COMPOSITIONS | March 2024 | November 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18608756 | DOSAGE FORMS OF MIRDAMETINIB | March 2024 | March 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18595206 | ASYMMETRIC ALLYL TRYPTAMINES | March 2024 | October 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18435547 | N-[(4,6-DIMETHYLPYRIMIDIN-2-YL)CARBAMOTHIOYL] PYRIDINE-3-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | February 2024 | August 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18430397 | 2-(1H-IMIDAZOLE-1-CARBONYL)BENZOIC ACID AS AN ANTICANCER COMPOUND | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18511663 | 1,3-BIS(NAPHTHALEN-1-YLOXY)PROPAN-2-ONE AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | November 2023 | March 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18486910 | N-[(4,6-DIMETHYLPYRIMIDIN-2-YL)CARBAMOTHIOYL] PYRIDINE-3-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | October 2023 | April 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18378255 | N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18369132 | 2-(1H-IMIDAZOLE-1-CARBONYL)BENZOIC ACID AS AN ANTICANCER COMPOUND | September 2023 | March 2025 | Abandon | 18 | 3 | 1 | No | No |
| 18463157 | SOLID FORMS OF ALPHA-1062 GLUCONATE | September 2023 | July 2024 | Allow | 10 | 0 | 1 | Yes | No |
| 18240886 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | August 2023 | September 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18239539 | 3,3'-(PIPERAZINE-1,4-DIYL)BIS(1-(NAPHTHALEN-2-YLOXY)PROPAN-2-OL) AS INSECTICIDAL AGENT | August 2023 | January 2024 | Allow | 5 | 1 | 1 | No | No |
| 18456379 | LYOPHILIZED PHARMACEUTICAL COMPOSITION AND USES OF A CRYSTALLIZED FORM OF LURBINECTEDIN | August 2023 | August 2024 | Abandon | 12 | 1 | 1 | Yes | No |
| 18225244 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | July 2023 | April 2024 | Allow | 9 | 1 | 1 | No | No |
| 18225234 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | July 2023 | February 2024 | Allow | 7 | 2 | 1 | Yes | No |
| 18309795 | Compositions and Methods for Treating COVID-19 and/or Acute Respiratory Failure and/or Acute Respiratory Distress Syndrome Using Tetrahydrocannabinol and Compositions Including Same | April 2023 | May 2024 | Abandon | 13 | 1 | 1 | No | No |
| 18297316 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | April 2023 | September 2023 | Allow | 5 | 1 | 0 | No | No |
| 18245624 | OLAPARIB OXALIC ACID COCRYSTALS AND THEIR PHARMACEUTICAL USE | March 2023 | February 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18044066 | CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3 | March 2023 | May 2025 | Allow | 26 | 4 | 0 | Yes | No |
| 18110261 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | February 2023 | June 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18154205 | CRYSTALLINE FORMS OF 3-(5-(2-HYDROXY-2-METHYLPROPOXY)-6-METHYLPYRAZIN-2-YL)-1H-INDOLE-7-CARBONITRILE | January 2023 | August 2024 | Allow | 19 | 0 | 1 | Yes | No |
| 18077350 | COMPOSITIONS COMPRISING COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE WITH TROMETHAMINE AND METHODS OF USE | December 2022 | July 2024 | Abandon | 20 | 2 | 0 | No | No |
| 17922581 | SARS-CoV-2 Antiviral Pharmaceutical Composition and Application Thereof | October 2022 | November 2023 | Abandon | 12 | 1 | 0 | No | No |
| 17934884 | BORTEZOMIB COMPOSITIONS | September 2022 | December 2023 | Abandon | 15 | 2 | 1 | Yes | No |
| 17818026 | Treatment for Diseases of Aging | August 2022 | April 2025 | Abandon | 33 | 2 | 1 | Yes | No |
| 17876096 | PHARMACEUTICAL COMPOSITIONS AND CRUSHABLE TABLETS INCLUDING AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES | July 2022 | January 2024 | Allow | 17 | 2 | 1 | No | No |
| 17867352 | METHODS OF MANUFACTURING 14,15-EPOXYEICOSATRIENOIC ACID ANALOGS AND IMPROVED THERAPEUTIC DELIVERY OF SAME | July 2022 | December 2023 | Allow | 17 | 2 | 1 | No | No |
| 17787510 | FORMULATIONS FOR USE IN THE TREATMENT OF DIFFERENT TYPES OF ADDICTIONS AND DEPENDENCE ON ADDICTIVE SUBSTANCES | June 2022 | November 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17839486 | CRYSTALLINE BORTEZOMIB PROCESS | June 2022 | January 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 17777985 | NEW SOLID STATE FORM OF LURBINECTEDIN | May 2022 | December 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17663669 | Novel Pharmaceutical Composition of Dimethylguanidino Valeric Acid and Plant Flavonoids for Treating Chronic Inflammatory Diseases and Cancer | May 2022 | June 2023 | Allow | 13 | 0 | 1 | Yes | No |
| 17739104 | ORONASAL CBD FORMULATIONS AND USES THEREOF | May 2022 | October 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17735276 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF PRURIGO NODULARIS | May 2022 | December 2024 | Allow | 31 | 4 | 0 | Yes | No |
| 17730129 | COMPOSITION FOR ZINC IONOPHORIC INFLUX AND TREATING INFLAMMATION | April 2022 | April 2025 | Abandon | 36 | 4 | 0 | Yes | No |
| 17728769 | Method of simultaneously treating viral disease caused coronavirus, its variants and mutants using a pharmaceutical micronutrient composition | April 2022 | April 2024 | Abandon | 24 | 1 | 1 | Yes | No |
| 17714553 | HEALTH SUPPLEMENT | April 2022 | January 2025 | Abandon | 34 | 2 | 1 | Yes | No |
| 17591186 | CRYSTALLINE FORMS OF A CYCLIN-DEPENDENT KINASE INHIBITOR | February 2022 | March 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17587380 | TREATMENTS FOR SKIN CONDITIONS | January 2022 | December 2024 | Abandon | 35 | 3 | 0 | No | No |
| 17577612 | INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS FOR CANCER IMMUNOTHERAPY | January 2022 | January 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17575025 | SOLID FORMS OF ALPHA-1062 GLUCONATE | January 2022 | August 2023 | Allow | 19 | 2 | 0 | No | No |
| 17571715 | ORGANIC ACYL HALOSULFONAMIDE BIOCIDE COMPOSITIONS AND METHODS OF MAKING AND USING THE COMPOSITIONS | January 2022 | May 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17564490 | COMPOSITIONS FOR THE MANAGEMENT OF DEMYELINATING DISORDERS | December 2021 | May 2025 | Abandon | 40 | 4 | 1 | Yes | No |
| 17556098 | PARENTERAL CANNABINOID FORMULATIONS AND USES THEREOF | December 2021 | April 2024 | Allow | 28 | 3 | 1 | Yes | No |
| 17617453 | Antibacterial Dosage Regime Using Cannabinoids | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17617322 | TRIAZOLE CARBOXYLIC ACIDS AS LPA ANTAGONISTS | December 2021 | April 2025 | Allow | 40 | 1 | 1 | No | No |
| 17535125 | MODULATION OF MOLECULAR MARKERS USING S-EQUOL | November 2021 | April 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17518590 | ANTIOXIDANT FOR USE IN TREATMENT FOR RIBE | November 2021 | August 2024 | Abandon | 33 | 3 | 0 | No | No |
| 17517197 | COMPOSITIONS COMPRISING VITAMINS/MINERALS IN A POLYPHENOLIC MATRIX, METHODS AND USES THEREOF | November 2021 | October 2023 | Allow | 24 | 1 | 0 | Yes | No |
| 17516400 | AQUEOUS COMPOSITIONS OF BORTEZOMIB | November 2021 | March 2024 | Allow | 28 | 2 | 0 | Yes | No |
| 17501667 | METHODS AND COMPOSITIONS FOR TREATING HUMAN PAPILLOMAVIRUS (HPV)-INDUCED CANCERS | October 2021 | April 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17594293 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | October 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17492978 | MRGX2 ANTAGONISTS | October 2021 | December 2023 | Allow | 26 | 1 | 1 | No | No |
| 17490492 | Combination Drug Substance of Polyamine Transport Inhibitor and DFMO | September 2021 | September 2023 | Allow | 23 | 2 | 0 | Yes | No |
| 17488430 | Halogenated Xanthenes as Vaccine Adjuvants | September 2021 | December 2023 | Allow | 26 | 3 | 0 | No | No |
| 17485858 | sGC STIMULATORS | September 2021 | June 2025 | Allow | 44 | 4 | 1 | Yes | No |
| 17486065 | COMPOSITION COMPRISING CAPSAICIN OR A CAPSACINOID FOR POSTOPERATIVE PAIN CONTROL | September 2021 | June 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17593650 | N-[l-(5-BROMO-2-PYRIMIDIN-2-YL-1,2,4-TRIAZOL-3-YL)ETHYL]-2-CYCLOPROPYL-6-(TRIFLUOROMETHYL)PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INSECTICIDES | September 2021 | March 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17482369 | TOPICAL CROTON LECHLERI COMPOSITIONS AND THEIR USE IN THE TREATMENT OF A BACTERIAL COLONIZATION OR PRIMARY OR SECONDARY BACTERIAL INFECTION OF AN UNDERLYING SKIN DISORDER | September 2021 | June 2025 | Allow | 45 | 4 | 0 | Yes | No |
| 17438767 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17469063 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE CRYSTALLINE FORMS | September 2021 | May 2023 | Allow | 20 | 1 | 0 | No | No |
| 17435230 | PHARMACEUTICAL COMPOSITION COMPRISING a-GALACTOSYLCERAMIDE AND/OR DENDRITIC CELLS PULSED WITH a-GALACTOSYLCERAMIDE | August 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17445792 | POLYMORPHS OF AN SSAO INHIBITOR | August 2021 | April 2023 | Allow | 19 | 1 | 0 | No | No |
| 17432589 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | August 2021 | June 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17430346 | COMBINATION THERAPIES FOR USE IN TREATING CANCER | August 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17430065 | METHODS AND COMPOSITIONS FOR INHIBITING THE NLRP3 INFLAMMASOME AND/OR LON PROTEASE | August 2021 | March 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17429885 | SUBSTITUTED AMINO-THIOL AND AMINO-DISULFIDE COMPOUNDS, AND USES THEREOF | August 2021 | April 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17429438 | POLYMORPHS OF INTEGRASE INHIBITOR | August 2021 | September 2024 | Allow | 38 | 0 | 1 | Yes | No |
| 17429269 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | August 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17395254 | Methods and Compositions for Microdosing, Simulating Extended Release Formulations | August 2021 | July 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17427811 | THERAPEUTIC COMBINATIONS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | August 2021 | November 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17443485 | USE OF A MIXTURE OF LAUROYL MACROGOLGLYCERIDE AND POLYETHYLENE GLYCOL AS AN EXCIPIENT | July 2021 | March 2024 | Allow | 32 | 2 | 0 | Yes | No |
| 17425124 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17353573 | ORONASAL CBD FORMULATIONS AND USES THEREOF | June 2021 | November 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17416064 | NITROGEN-CONTAINING FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | June 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17312480 | ARGINASE INHIBITORS AND METHODS OF USE | June 2021 | September 2024 | Allow | 39 | 1 | 1 | No | No |
| 17338283 | PERSONALIZED METHODS OF TREATING CANCER | June 2021 | July 2024 | Allow | 37 | 3 | 0 | Yes | No |
| 17297913 | PHARMACEUTICAL APPLICATION OF DIMYRICETIN-BASED DISELENIDE | May 2021 | June 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17291793 | COMBINATION OF PRMT5 INHIBITORS AND BCL-2 INHIBITORS | May 2021 | December 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17290939 | DIHYDROMYRICETIN WITH ANTI-ALCOHOLIC EFFECT | May 2021 | April 2025 | Abandon | 47 | 2 | 0 | Yes | No |
| 17283843 | TREATMENT OF DISEASES ASSOCIATED WITH BILIARY SYSTEM DESTRUCTION | April 2021 | April 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17217524 | STIMULUS-RESPONSIVE ANTIOXIDANT CRYSTALS AND METHOD FOR THEIR PREPARATION | March 2021 | December 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17279751 | AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF | March 2021 | March 2025 | Allow | 48 | 3 | 1 | Yes | No |
| 17211823 | FISETIN COMPOSITION AND A METHOD OF MAKING THE SAME | March 2021 | July 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17212723 | Uses of Halogenated Xanthenes in Oncology and Virology | March 2021 | March 2024 | Allow | 35 | 3 | 1 | Yes | No |
| 17211778 | METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASES | March 2021 | July 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17279525 | MEDICAL APPLICATION OF PYRIMIDINE SULFONAMIDES DERIVATIVES | March 2021 | December 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 17203758 | COMPOUND AND USE THEREOF | March 2021 | July 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17200854 | AURORA KINASE INHIBITORS AND USES THEREOF | March 2021 | May 2025 | Allow | 50 | 3 | 1 | Yes | No |
| 17274600 | METHODS FOR THE TREATMENT OF NEUROFIBROMATOSIS | March 2021 | April 2025 | Abandon | 49 | 5 | 1 | No | No |
| 17184350 | METHODS OF USING CANNABINOIDS FOR INHIBITING INDUCTION OF VIRULENCE IN ENTERIC PATHOGENS | February 2021 | May 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17173416 | GPX4 INHIBITOR IN COMBINATION WITH ANTICANCER AGENT FOR TREATING PROLIFERATIVE DISEASE | February 2021 | January 2024 | Allow | 35 | 3 | 0 | No | No |
| 17168524 | CANNABINOID-CONTAINING EXTRACTS, FORMULATIONS, AND USES THEREOF FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | February 2021 | December 2023 | Abandon | 34 | 2 | 0 | No | No |
| 17261982 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | January 2021 | January 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17154261 | Crystalline Forms of Zuclomiphene Citrate | January 2021 | February 2023 | Allow | 25 | 1 | 1 | No | No |
| 17260691 | HERBICIDAL MIXTURES COMPRISING ISOXAFLUTOLE, PYROXASULFONE AND AN IMIDAZOLINONE HERBICIDE; AND THEIR USE IN SOYBEAN AND COTTON CULTURES | January 2021 | May 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17260124 | METHODS OF UPREGULATING TIPARP AS ANTICANCER STRATEGIES | January 2021 | April 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17252214 | DECREASING IMMUNE ACTIVITY THROUGH MODULATION OF POSTCELLULAR SIGNALING FACTORS | December 2020 | September 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17058065 | CANNABIS-BASED COMPOSITIONS FOR THE TREATMENT OF AUTISTIC SPECTRUM DISORDERS | November 2020 | April 2024 | Abandon | 40 | 0 | 1 | No | No |
| 16952887 | Methods of Treating Brain Cancer and Related Diagnostic Methods | November 2020 | September 2023 | Abandon | 34 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GONZALEZ, LUISALBERTO.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner GONZALEZ, LUISALBERTO works in Art Unit 1624 and has examined 110 patent applications in our dataset. With an allowance rate of 53.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner GONZALEZ, LUISALBERTO's allowance rate of 53.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GONZALEZ, LUISALBERTO receive 1.51 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by GONZALEZ, LUISALBERTO is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +53.5% benefit to allowance rate for applications examined by GONZALEZ, LUISALBERTO. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 38.2% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 35.0% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 29.4% are granted (fully or in part). This grant rate is in the 21% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.2% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.